News - EDF EN Canada announces the commercial operation of the Massif du Sud Wind Project (150 MW) and the first phase of the Lac Alfred Wind Project (150 MW) both located in Quebec. Massif du Sud and Lac Alfred represent two of the seven wind energy projects in total awarded to the company in 2008 and 2010 through Hydro-Quebec Distribution calls for tenders. By the end of 2015, EDF EN Canada will have developed and built a total of 1,003.2 MW in the province. With a combined investment (Massif du Sud and Lac Alfred Phase I) of close to $700 million, the projects together created more than 600 jobs during the construction phase, and will provide 20-30 permanent operations and maintenance jobs.
News - EnGlobe Corp. is pleased to announce that it has been awarded by the State of Israel an environmental service contract valued at over 40 million dollars for the rehabilitation of the Kishon River located in the Haifa Bay in Israel. With its biotreatment technology (Biopile) developed and improved over the last 30 years, EnGlobe and its Biogénie division will have the responsibility of decontaminating over half a million cubic meters of sediments, in addition to supervising the construction of the future recreational and ecological park that will benefit to all Haifa residents and the surroundings.
News - The French-American Chamber of Commerce, Washington DC, is very pleased to partner with Québec International and Montréal International for the organization of a two-day recruiting event on March 22nd. Mrs. Line Lagacé, Vice-president, Business Growth and Foreign Investment of Québec International and Mr. Louis Arseneault, Vice President, Talent Attraction, Promotion and Communications, Montréal International answer our questions! Interview in English and in French.
News - Quebec-based CO2 Solutions has been granted three U.S. patents for the capture of carbon emissions from any gas stream with any aqueous solvent or solution. The Quebec City company that works in the enzyme-enabled carbon capture technology field said the three patents cover the use of the enzyme carbonic anhydrase flowing through an absorption reactor.
News - Medicago announced the execution of $15,000,000 loan agreement with a major Pharmaceutical company. The principal of the loan is repayable on January 14, 2014 but can be extended by Medicago at its option until January 14, 2016 and will bear an interest rate of not more than 10% per year. Interest on this loan will be paid quarterly.
News - Anges Québec is pleased to announce $1M in financing granted to handyem, a Quebec company specializing in life science. The financing comes from 19 Anges Québec members and the Anges Québec Capital Fund. Of this amount, $680K is from Anges Québec members, including Stéphane Pilette, and $320K from the fund. An additional amount in excess of $700K comes from existing shareholders and new private investors, bringing the current round of financing to $1.7M.
News - Genetics plays a major role in peer rejection and victimization in early elementary school, according to a study recently published on the website of the journal Child Development by a team directed by Dr. Michel Boivin, a research professor at Université Laval’s School of Psychology.
News - CO2 Solutions announced it will receive $348,000 in non-reimbursable funding from the National Research Council Canada's Industrial Research Assistance Program. The funding will be used to support the ongoing development of CO2 Solutions' technology, including enzyme evolution and enzyme management process optimization work and will be disbursed over the next twelve months.
News - Lens Vector recently reached a new milestone in the marketing of its product, the smallest autofocus lens available without any moving parts. The lens is now integrated in an HD webcam released to the general public by CREATIVE. It is worth recalling that the technology emerged from the work of Professor Tigran Galstian and his research team at Université Laval.
News - A team of researchers from Université Laval, CHU de Québec, and pharmaceutical firm GlaxoSmithKline (GSK) has discovered a way to stimulate the brain’s natural defense mechanisms in people with Alzheimer’s disease. This major breakthrough, details of which are presented today in an early online edition of the Proceedings of the National Academy of Sciences (PNAS), opens the door to the development of a treatment for Alzheimer’s disease and a vaccine to prevent the illness.